Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
76°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aura Biosciences, Inc.
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 27, 2024
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
November 09, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Proposed Public Offering of Common Stock
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
February 16, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 30, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Proposed Public Offering of Common Stock
November 30, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
November 10, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
October 03, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
September 28, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
September 27, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
August 02, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
June 30, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference
November 23, 2021
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Pricing of Initial Public Offering
October 28, 2021
From
Aura Biosciences, Inc.
Via
Business Wire
Tickers
AURA
Aura Biosciences Announces Publication of Data in Cancer Immunology Research, Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment
April 14, 2021
From
Aura Biosciences, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.